Controversy. Dabigatran in the preventive treatment embolic stroke: Against its use as first-line drug;Controversia. dabigatrán en el tratamiento preventivo del ictus embólico: En contra de su utilización como fármaco de primera línea

Revista de Neurologia

Volumn 54, Issue 5, 2012, Pages 260-262

  Calleja Puerta, Sergio ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE; N ((2 (((4 (AMINOIMINOMETHYL)PHENYL)AMINO)METHYL) 1 METHYL 1H BENZIMIDAZOL 5 YL)CARBONYL) N 2 PYRIDINYL BETA ALANINE; N-((2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-BETA-ALANINE;

ARTICLE; EMBOLIC STROKE; EMBOLISM; STROKE; BRAIN EMBOLISM; CEREBROVASCULAR ACCIDENT; HUMAN;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; INTRACRANIAL EMBOLISM; STROKE;

EID: 84857845559     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5405.2012068     Document Type: Article

References (8)

1. Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol 2010; 196: 407-18.
2. Schiff GD, Galanter WL, Duhig J, Lodolce AE, Koronkowski MJ, Lambert BL. Principles of conservative prescribing. Arch Intern Med 2011; 171: 1433-40.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-6.
4. Therapeutics Initiative. Dabigatran for atrial fibrillation. Why we can not rely on RE-LY. URL: http://www.ti.ubc.ca/sites/ti.ubc.ca/files/80.pdf. [04.02.2012].
5. Uchino K, Hernández AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; Jan 9. [Epub ahead of print].
6. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-83.
7. FDA Drug Safety Communication: safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). URL: http://www.fda.gov/drugs/drugsafety/ucm282724.htm. [16.02.2012].
8. Heneghan C, Ward A, Perera R. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379: 322-34.